Drugs /

ptk7-adc

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for ptk7-adc

Ptk7-adc has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ptk7-adc, 1 is phase 1 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ptk7-adc clinical trials.

Breast carcinoma is the most common disease being investigated in ptk7-adc clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ptk7-Adc
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ptk7-adc and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
PTK7

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.